Related Experiment Video
Updated: Nov 15, 2025
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
Development and Validation of an LC-MS/MS Method for AC1LPSZG and Pharmacokinetics Application in Rats
Yuan Chen1, Xiuqing Gao1, Ritu Gupta1
1Department of Pharmaceutical and Environmental Health Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.
Abstract:
Promising preliminary clinical data have stimulated research on the use of the mammalian target of rapamycin (mTOR) inhibitors in lung cancer. AC1LPSZG is an mTOR inhibitor that can significantly reduce the viability in lung adenosquamous carcinoma cell line HTB-178 cells, showing potential benefits in effective control of non-small cell lung carcinomas. In this study, a sensitive LC-MS/MS analytical method for quantification of AC1LPSZG has been developed and optimized to a running time of 3 min per sample. A linear dose-response for quantification was observed over the range of 10-5000 ng/mL in rat plasma with required precision and accuracy. High extraction recovery was achieved in the ranges of 86.87-102.51% at QC levels from rat plasma without significant matrix effect. Stability profile of AC1LPSZG in rat plasma and in extract after protein precipitation suggested that samples should be processed within 6 h after collection and stored at -80 °C until analysis within 30 days. The method was successfully applied to plasma pharmacokinetics (PK) study of AC1LPSZG in rat, showing the plasma drug concentration followed a two-compartment model.
Insights
A new liquid chromatography-tandem mass spectrometry method quantifies AC1LPSZG, an mTOR inhibitor, in rat plasma. This method supports pharmacokinetic studies for potential lung cancer treatments.
Area of Science:
- Pharmacology
- Analytical Chemistry
- Oncology
Background:
- Mammalian target of rapamycin (mTOR) inhibitors show promise in lung cancer treatment.
- AC1LPSZG, an mTOR inhibitor, demonstrates efficacy against lung adenosquamous carcinoma cell lines.
- Effective quantification methods are crucial for developing AC1LPSZG as a lung cancer therapy.
Purpose of the Study:
- To develop and validate a sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for quantifying AC1LPSZG in rat plasma.
- To assess the stability of AC1LPSZG in plasma and processed samples.
- To apply the validated method in a rat pharmacokinetic study.
Main Methods:
- Development and optimization of an LC-MS/MS assay for AC1LPSZG.
- Validation of the method for linearity, precision, accuracy, extraction recovery, and matrix effect in rat plasma.
- Assessment of AC1LPSZG stability under various conditions.
- Application of the method to a rat plasma pharmacokinetic study.
Main Results:
- A rapid (3-min run time) and sensitive LC-MS/MS method was established.
- The method demonstrated excellent linearity (10-5000 ng/mL), precision, and accuracy in rat plasma.
- High extraction recovery (>86%) and minimal matrix effect were observed.
- AC1LPSZG stability was confirmed under specified processing and storage conditions.
- The method successfully elucidated the plasma pharmacokinetics of AC1LPSZG in rats, following a two-compartment model.
Conclusions:
- A validated LC-MS/MS method enables sensitive and efficient quantification of AC1LPSZG in rat plasma.
- The method is suitable for supporting preclinical pharmacokinetic studies of AC1LPSZG.
- Pharmacokinetic data suggest AC1LPSZG follows a two-compartment distribution in rats, informing further drug development for lung cancer.
